Rheonix has been granted an expanded EUA for the Rheonix COVID-19 MDx Assay, now allowing the use of saliva as an approved sample type. The fully automated, sample-to-answer assay was initially authorized for use on a range of respiratory specimens under EUA in April 2020. The assay is processed on the fully automated Rheonix Encompass MDx workstation using proprietary Rheonix CARD cartridge technology. The system requires minimal training to use and can be quickly installed in critical locations for immediate need. It provides same-day results and is highly scalable, enabling laboratories to move from outsourcing their COVID-19 testing to providing same- or next-day test results. Rheonix has increased its manufacturing capacity, committing reagent availability to support laboratories’ ongoing testing requirements.

Rheonix, Inc